Myocardial Ketone Body Oxidation Contributes to Empagliflozin-Induced Improvements in Cardiac Contractility in Murine Heart Failure
Open Access
- 11 March 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 27 (7) , 1353-1358
Abstract
Aims: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood. We sought to determine whether SGLT2i-induced improvements in cardiac function are dependent on increased cardiac oxidation of ketone bodies. Methods and results: We employed a mouse model with a cardiac-specific knock-out of the enzyme D-β-hydroxybutyrate dehydrogenase-1 (BDH1cko), rendering mice incapable of oxidizing the principal ketone body β-hydroxybutyrate in cardiomyocytes. Male BDH1cko and littermate controls underwent either permanent coronary artery ligation of the left anterior descending coronary artery to induce myocardial infarction (MI) or sham surgery. Two weeks after surgery, mice were randomized to 6 weeks of empagliflozin or vehicle treatment. Cardiac function was assessed using transthoracic echocardiography before and after treatment, and histological and molecular analyses were performed after sacrifice. Empagliflozin treatment resulted in a twofold increase in circulating ketone bodies. Mean infarct size (36 ± 4% of the left ventricle) was comparable among MI groups. In control mice, empagliflozin treatment resulted in a significant increase in left ventricular ejection fraction (LVEF) whereas LVEF remained stable in the vehicle treated group (ΔLVEF −1.1 ± 2.2% vs. 5.2 ± 1.5%, p < 0.05). Empagliflozin did not influence cardiac contractility in BDH1cko mice (ΔLVEF −5.9 ± 2.1% vs. −1.5 ± 2.8%, p = 0.213). Other echocardiographic, histological and molecular signatures of adverse myocardial remodelling were not affected by empagliflozin treatment. Conclusion: The beneficial effects of empagliflozin on cardiac contractility in post-MI heart failure are attenuated in mice which are incapable of oxidizing the ketone body β-hydroxybutyrate in their hearts. These findings suggest that enhanced cardiac ketone body oxidation contributes to the cardioprotective effects of SGLT2i.Keywords
This publication has 32 references indexed in Scilit:
- Pleiotropic effects of SGLT2 inhibitors and heart failure outcomesDiabetes Research and Clinical Practice, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular DiseaseJACC, 2021
- Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart FailureJACC: Cardiovascular Imaging, 2021
- Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection FractionJACC, 2021
- Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction After Myocardial InfarctionEuropean Journal of Heart Failure, 2019
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial EnergeticsJACC, 2019
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat heartsFree Radical Biology and Medicine, 2017
- Empagliflozin’s Fuel Hypothesis: Not so SoonCell Metabolism, 2016
- The liver X Receptor Agonist AZ876 Protects Against Pathological Cardiac Hypertrophy and Fibrosis Without Lipogenic Side EffectsEuropean Journal of Heart Failure, 2015